Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...
Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...
Switzerland's Novartis on Thursday projected currency-adjusted sales growth of 5% to 6% until 2030 for the group, underpinned ...
Data from a new surveillance report show rising resistance to ceftriaxone and cefixime, the two antibiotics currently ...
Novo Nordisk is expected to announce soon whether its blockbuster GLP-1 drug semaglutide can help slow Alzheimer’s disease ...
The United States said Tuesday it has delivered a new treatment to prevent HIV in two African countries, months after President Donald Trump dramatically cut global aid.
Eswatini has become the first African country to receive lenacapavir, a twice-yearly HIV prevention injection that global ...
3d
NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position
NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2025 with the Securities and Exchange ...
The Pennsylvania Department of Health will cut 25% of funding to the Part B of the Ryan White HIV/AIDS Program amid rising ...
UBS Global Healthcare Conference 2025 November 10, 2025 11:00 AM ESTCompany ParticipantsAndrew Dickinson - Chief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback